Looking for first-in-class glory, Boehringer Ingelheim acquires two preclinical cancer drugs from Versant-backed biotech
Wading deeper into the next wave of immuno-oncology, Boehringer Ingelheim has bought up a Versant-launched preclinical pipeline focused on the tumor microenvironment.
The acquisition of Northern Biologics — a subsidiary of the Toronto-based biotech Northern LP — positions Boehringer at the forefront of the stromal biology space, the company said. Northern Biologics will continue plowing on the preclinical front until the German pharma takes over the clinical, regulatory and commercial work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.